In head-to-head lab comparisons, quercetin outperforms cromolyn — an actual pharmaceutical mast cell stabiliser — at blocking the release of histamine, prostaglandin D2 and leukotrienes from human mast cells. The mechanism reaches well past hay fever season.
Every August the same conversation happens: a client's eyes are streaming, their nose is blocked, and they've tried the antihistamine from the pharmacy and it's taking the edge off but not solving it. Quercetin is not a hay fever remedy in the way people usually mean that phrase. It's a flavonoid that changes what mast cells do — and pollen season just happens to be when that matters most visibly.
Quercetin is a plant flavonoid found in onions, apples, capers and buckwheat, among others — dietary intake is real but modest, which is why supplemental doses used in trials are well above what food alone provides. It's been studied for decades across cardiovascular, anti-inflammatory and antihistamine research, but the mast cell mechanism is where the evidence is most directly actionable.
Mast cells release histamine, prostaglandin D2 and leukotrienes when triggered — by pollen, by food, by physical stimuli in more sensitised presentations. Quercetin reduces intracellular calcium influx in the mast cell, which is the step that triggers degranulation. Less calcium influx means less mediator release, before the cascade that produces the itching, swelling and congestion even starts.
A 2012 in vitro comparison found quercetin more effective than cromolyn — a licensed pharmaceutical mast cell stabiliser — at blocking cytokine release from human mast cells, and effective prophylactically in a way cromolyn isn't (cromolyn has to be present at the moment of the trigger; quercetin's effect persists when taken ahead of exposure).
The mast cell stabilisation mechanism is well established in laboratory and animal work, with direct comparison against a known pharmaceutical stabiliser. Human trial evidence for seasonal allergic rhinitis is smaller in scale but consistent in direction — participants taking 500mg daily for 8 weeks reported measurable reductions in nasal symptoms and eye itching compared to placebo. This isn't the ambiguous, oversold territory a lot of "natural antihistamine" claims live in; the mechanism and the clinical direction agree with each other.
Prophylactic/seasonal use: 500mg once or twice daily, started 2–3 weeks before the person's typical pollen onset — not on the day symptoms start. The stabilising effect builds; it isn't an acute antihistamine.
Mast cell / histamine-sensitive presentations: studies more often use 500–1,000mg daily in divided doses, but this is a context where individual titration and clinical supervision matter more than a fixed number.
Absorption: quercetin aglycone has poor bioavailability on its own. Look for a quercetin phytosome (bound to phosphatidylcholine) or a formulation paired with bromelain, both of which meaningfully improve absorption over plain quercetin powder in a capsule.
Quercetin isn't just for hay fever. If a client's OAT or symptom picture points toward histamine intolerance or mast cell involvement — flushing, unexplained hives, symptoms that worsen with high-histamine foods, or a pattern of reactivity across multiple systems that doesn't fit a single food sensitivity — quercetin sits alongside DAO support and a lower-histamine approach as one of the more evidence-backed tools available. It also has a genuine, if secondary, connective tissue angle: quercetin's inhibition of mast cell tryptase release is relevant in hypermobile and connective-tissue-sensitive presentations where mast cell activity is contributing to tissue symptoms, not just allergic ones.
The prophylactic framing is the part people miss. Taken after symptoms start, it's doing very little that an antihistamine doesn't already do faster. Taken three weeks before the pollen count rises, it's addressing the mechanism before it fires.
Quercetin is not a substitute for identifying and addressing what's actually driving mast cell over-activation in the first place — gut permeability, chronic infection, mould exposure and connective tissue laxity are all upstream drivers worth investigating rather than just damping the downstream histamine response indefinitely. It's a genuinely useful tool. It isn't the whole answer.
Ask AIdan for a read on your supplement stack, or find out whether mast cell involvement shows up in your testing.
Ask AIdan → See the TDG Programme